Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02256618Phase 1Completed

Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy

Role: collaborator

NCT02455830Unknown

Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy

Role: collaborator

NCT01574586Not ApplicableUnknown

Bifurcation Stenting Using 2 Link Stent Nobori Versus 3 Link Stent Xience

Role: lead

NCT01889459Recruiting

Japanese CTO PCI Expert Registry

Role: lead

All 4 trials loaded